Abstract 1579P
Background
Worldwide, AYA care for patients < 25 years is mostly delivered by paediatric oncologists. For the whole range of patients at AYA age (15- 39 years) there is a need for AYA care in adult oncology practices. In 2014, a national AYA network with central coordination, started in the Netherlands (NL) in 7 university medical centres and a cancer centre, with the aim to extend to a nationwide network in the adult oncology environment. This network, co-designed by healthcare professionals (HCPs), patients and caregivers, has evolved towards a data driven learning healthcare system and may be a model for other countries as well.
Methods
From its start, with very limited resources, annual plans were made with lean deliverables, topics on AYA care domains were addressed, (mandatory) teaching modules for HCPs have been developed, and AYA research projects were written with the aim to constantly feed data into the educational and care initiatives of the network.
Results
In ten years, the number of hospitals delivering AYA care has expanded to 75; since 2024 AYA care and network-management is reimbursed by healthcare insurance companies. Research projects have been awarded from the Dutch Cancer Society, Dutch Scientific Council and EU Horizon program. COMPRAYA – a prospective study to collect clinical, biological and psychosocial data, GENAYA - a collection of whole genome sequencing data, INVAYA and CORDAYA –research projects for AYAs with an uncertain or poor prognosis and SURVAYA investigating AYAs 5-20 years after diagnosis, all generate data to constantly improve AYA care. Our awarded EU project STRONG AYA, with federated data collection running in NL, UK, France, Poland and Italy will generate data for individual countries and will ensure benchmarking to improve AYA care at pan-European level. Results of projects are evaluated regularly by master and PhD students with medical, psychosocial and econometry background and postdoctoral researchers, supervised by the core team. Teaching modules are adapted and developed based on the obtained data.
Conclusions
The model of a learning AYA-healthcare system enables collaborative (inter)national data driven initiatives, which has the advantage to improve AYA care at an (inter)national and local level.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1573P - Global cancer statistics for adolescents and young adults: New estimates from GLOBOCAN 2022
Presenter: Wang-Zhong Li
Session: Poster session 10
Resources:
Abstract
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1582P - Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Poster session 10
1583P - Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade
Presenter: Luís Leite
Session: Poster session 10